AstraZeneca Urges Fed. Circ. To Rethink IP Ruling For Mylan
AstraZeneca wants the Federal Circuit to rethink a split panel decision that gave Mylan another chance to try to show that its planned generic of inhaler asthma treatment Symbicort doesn't infringe...To view the full article, register now.
Already a subscriber? Click here to view full article